Error loading player: No playable sources found
Session V: Multispecifics and ADCs Characterization
Date
September 12, 2024
This product is not available for individual purchase, but it is available as part of the following products:
Session Chairs: Chris Chumsae, Bristol-Myers Squibb Company and Frances Namuswe, CDER, FDA
Session Speakers:
Glyco-Analysis of a Glycoengineered VHH-Radioligand Therapy Designed for Improved Biodistribution
David Bush, Novartis
Characterization of ADCs in Serum and Formulation Buffer
Tun Liu, Johnson & Johnson
Development of Novel Chromatographic and Mass Spectrometric Techniques for Characterizations of BsAbs and ADCs
Fengfei Ma, Merck & Co., Inc.
Session Chairs
Speakers
Related Products
Session VII: MS Trends in Regulatory Research, Review, and Standard
Session Chairs: Sarah Rogstad_, CDER, FDA,_ and Frances Namuswe, _CDER, FDA_
Session VIII: MAM for Product & Process Characterization & Quality Control
Session Chairs: Ingo Lindner,_ Roche Diagnostics GmbH_ and Da Ren, _BioTherapeutics Solutions_
Session III: Joint MS/HOS Plenary Session: Mass Spec Technologies in HOS / Comprehensive Toolboxes for Complex Problems
Session Chair: Frances Namuswe, _CDER, FDA_
Session II: Mass Spectrometry in Cell & Gene Therapy
Session Chairs: : Rich Rogers,_ Umoja Biopharma_ and Chris Yu, _Genentech, __A Member of the Roche Group_
